613 related articles for article (PubMed ID: 26137574)
41. Prevention and treatment of alopecia areata with quercetin in the C3H/HeJ mouse model.
Wikramanayake TC; Villasante AC; Mauro LM; Perez CI; Schachner LA; Jimenez JJ
Cell Stress Chaperones; 2012 Mar; 17(2):267-74. PubMed ID: 22042611
[TBL] [Abstract][Full Text] [Related]
42. Inhibiting Janus kinases to treat alopecia areata.
Divito SJ; Kupper TS
Nat Med; 2014 Sep; 20(9):989-90. PubMed ID: 25198048
[TBL] [Abstract][Full Text] [Related]
43. The Good and Bad News About New Drugs for Treating Alopecia Areata.
Morgado-Carrasco D; Rodríguez-Lobato E; Riera-Monroig J; Ferrando J
Actas Dermosifiliogr (Engl Ed); 2018; 109(1):69-70. PubMed ID: 28641742
[No Abstract] [Full Text] [Related]
44. Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway.
Sardana K; Bathula S; Khurana A
Indian Dermatol Online J; 2023; 14(4):465-474. PubMed ID: 37521227
[TBL] [Abstract][Full Text] [Related]
45. Emerging drugs for alopecia areata: JAK inhibitors.
Iorizzo M; Tosti A
Expert Opin Emerg Drugs; 2018 Mar; 23(1):77-81. PubMed ID: 29466675
[TBL] [Abstract][Full Text] [Related]
46. Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Kotyla PJ
Biomed Res Int; 2018; 2018():7492904. PubMed ID: 29862290
[TBL] [Abstract][Full Text] [Related]
47. Overview of alopecia areata for managed care and payer stakeholders in the United States.
King B; Pezalla E; Fung S; Tran H; Bourret JA; Peeples-Lamirande K; Takiya L; Napatalung L
J Manag Care Spec Pharm; 2023 Jul; 29(7):848-856. PubMed ID: 37219075
[TBL] [Abstract][Full Text] [Related]
48. Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata.
Dai Z; Sezin T; Chang Y; Lee EY; Wang EHC; Christiano AM
Front Immunol; 2022; 13():955038. PubMed ID: 36203601
[TBL] [Abstract][Full Text] [Related]
49. Baricitinib for alopecia areata.
Imran H; Hoda F; Shakil F
J Pak Med Assoc; 2023 May; 73(5):1172. PubMed ID: 37218276
[No Abstract] [Full Text] [Related]
50. RF - Recent Approval of Baricitinib for Alopecia Areata: Safety and Efficacy Data.
Corbella-Bagot L; Luque-Luna M; Morgado-Carrasco D
Actas Dermosifiliogr; 2023 Sep; 114(8):718-719. PubMed ID: 36933614
[No Abstract] [Full Text] [Related]
51. Comment on ‘Treatment of moderate-to-severe alopecia areata in preadolescent children with baricitinib’: authors’ reply.
Asfour L; Bokhari L; Bhoyrul B; Eisman S; Moussa A; Rees H; Sinclair RD
Br J Dermatol; 2023 Dec; 190(1):136-137. PubMed ID: 37596774
[No Abstract] [Full Text] [Related]
52. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.
Kubo S; Nakayamada S; Tanaka Y
Expert Rev Clin Immunol; 2019 Jul; 15(7):693-700. PubMed ID: 30987474
[No Abstract] [Full Text] [Related]
53. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
Mogul A; Corsi K; McAuliffe L
Ann Pharmacother; 2019 Sep; 53(9):947-953. PubMed ID: 30907116
[No Abstract] [Full Text] [Related]
54. Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome.
Boyadzhiev M; Marinov L; Boyadzhiev V; Iotova V; Aksentijevich I; Hambleton S
Pediatr Rheumatol Online J; 2019 May; 17(1):19. PubMed ID: 31046790
[TBL] [Abstract][Full Text] [Related]
55. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
Freyschmidt-Paul P; Sundberg JP; Happle R; McElwee KJ; Metz S; Boggess D; Hoffmann R
J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620
[TBL] [Abstract][Full Text] [Related]
56. Baricitinib improved alopecia areata concomitant with atopic dermatitis: A case report.
Uchida H; Kamata M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Dermatol; 2021 Sep; 48(9):e472-e473. PubMed ID: 34151450
[No Abstract] [Full Text] [Related]
57. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
Ko JM; Mayo TT; Bergfeld WF; Dutronc Y; Yu G; Ball SG; Somani N; Craiglow BG
JAMA Dermatol; 2023 Sep; 159(9):970-976. PubMed ID: 37556146
[TBL] [Abstract][Full Text] [Related]
58. Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts.
McElwee KJ; Boggess D; King LE; Sundberg JP
J Invest Dermatol; 1998 Nov; 111(5):797-803. PubMed ID: 9804341
[TBL] [Abstract][Full Text] [Related]
59. Effectiveness and safety of baricitinib in patients with alopecia areata: a systematic review and Meta-analysis of randomized controlled trials.
Mahmoud AM
Curr Med Res Opin; 2023 Feb; 39(2):249-257. PubMed ID: 36239359
[TBL] [Abstract][Full Text] [Related]
60. Application of Baricitinib in Dermatology.
Zhang J; Qi F; Dong J; Tan Y; Gao L; Liu F
J Inflamm Res; 2022; 15():1935-1941. PubMed ID: 35330989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
